Philadelphia, August 24, 2020 - Autism is a neurodevelopmental condition that researchers are now tracing back to prenatal development, even though the disorder is not diagnosed until at least 18 months of age. A new study now shows in human brain cells that the atypical development starts at the very earliest stages of brain organization, at the level of individual brain cells.
The study from scientists at King's College London and Cambridge University, UK appears in Biological Psychiatry, published by Elsevier.
Deepak Srivastava, PhD, from the MRC Centre for Neurodevelopmental Disorders and Department of Basic and Clinical Neuroscience at King's College London, who supervised the study, said: "In this study we used induced pluripotent stem cells, or iPSCs, to model early brain development. Our findings indicate that brain cells from autistic people develop differently to those from typical individuals."
The researchers isolated hair samples from nine autistic people and six typical people. By treating the cells with an array of growth factors, the scientists were able to drive the hair cells to become nerve cells, or neurons--much like those found in either the cortex or the midbrain region. iPSCs retain the genetic identity of the person from which they came and the cells re-start their development as it would have happened in the womb, providing a window into that person's brain development.
Dwaipayan Adhya, PhD, a molecular biologist at the Autism Research Centre in Cambridge and Department of Basic and Clinical Neuroscience at King's College London, said: "Using iPSCs from hair samples is the most ethical way to study early brain development in autistic people. It bypasses the need for animal research, it is non-invasive and it simply requires a single hair or skin sample from a person."
At various stages, the authors examined the developing cells' appearance and sequenced their RNA, to see which genes the cells were expressing.
At day 9, developing neurons from typical people formed "neural rosettes," an intricate, dandelion-like shape indicative of typically developing neurons. Cells from autistic people formed smaller rosettes or did not form rosettes at all. And key developmental genes were expressed at lower levels in cells from autistic people.
At days 21 and 35, the cells from typical and autistic people differed significantly in a number of ways, suggesting that the makeup of neurons in the cortex differs in the autistic and typically developing brain.
John Krystal, PhD, Editor-in-Chief of Biological Psychiatry, said of the findings: "The emergence of differences associated with autism in these nerve cells shows that these differences arise very early in life."
In contrast to the differences seen in cortical neurons, cells directed to develop as midbrain neurons - a brain region not implicated in autism dysfunction - showed only negligible differences between typical and autistic people.
"The use of iPSCs allows us to examine more precisely the differences in cell fates and gene pathways that occur in neural cells from autistic and typical individuals. These findings will hopefully contribute to our understanding of why there is such diversity in brain development," said Dr. Srivastava.
Simon Baron-Cohen, PhD, Director of the Autism Research Centre at Cambridge, who co-led the study, added, "Some people may be worried that basic research into differences in the autistic and typical brain prenatally may be intended to 'prevent,' 'eradicate,' or 'cure' autism. This is not our motivation, and we are outspoken in our values in standing up against eugenics and in valuing neurodiversity. Such studies will lead to a better understanding of brain development in both autistic and typical individuals."
"The brain has been the ultimate black box. Here, the authors have used nerve cells derived from peripheral stem cells to peek inside this box. This important study suggests that this is possible and is deepening our understanding of autism," Dr. Krystal added.
###
Notes for editors
The article is "Atypical neurogenesis in induced pluripotent stem cell (iPSC) from autistic individuals," by Dwaipayan Adhya, Vivek Swarup, Roland Nagy, Lucia Dutan, Carole Shum, Eva Valencia-Alarcón, Kamila Maria Jozwik, Maria Andreina Mendez, Jamie Horder, Eva Loth, Paulina Nowosiad, Irene Lee, David Skuse, Frances Flinter, Declan Murphy, Grainne McAlonan, Daniel Geschwind, Jack Price, Jason Carroll, Deepak Srivastava, and https://doi.org/10.1016/j.biopsych.2020.06.014">Simon Baron-Cohen. It appears as an Article in Press in Biological Psychiatry, published by Elsevier.Copies of this paper are available to credentialed journalists upon request; please contact Rhiannon Bugno at biol.psych@sobp.org or +1 254 522 9700. Journalists wishing to interview the authors may contact Franca Davenport at franca.davenport@kcl.ac.uk or +44 20 7848 5377 / +44 7718 697176.
The authors' affiliations and disclosures of financial and conflicts of interests are available in the article.
John H. Krystal, MD, is Chairman of the Department of Psychiatry at the Yale University School of Medicine, Chief of Psychiatry at Yale-New Haven Hospital, and a research psychiatrist at the VA Connecticut Healthcare System. His disclosures of financial and conflicts of interests are available here.
About Biological Psychiatry
Biological Psychiatry is the official journal of the Society of Biological Psychiatry, whose purpose is to promote excellence in scientific research and education in fields that investigate the nature, causes, mechanisms and treatments of disorders of thought, emotion, or behavior. In accord with this mission, this peer-reviewed, rapid-publication, international journal publishes both basic and clinical contributions from all disciplines and research areas relevant to the pathophysiology and treatment of major psychiatric disorders.The journal publishes novel results of original research which represent an important new lead or significant impact on the field, particularly those addressing genetic and environmental risk factors, neural circuitry and neurochemistry, and important new therapeutic approaches. Reviews and commentaries that focus on topics of current research and interest are also encouraged.
Biological Psychiatry is one of the most selective and highly cited journals in the field of psychiatric neuroscience. It is ranked 7th out of 155 Psychiatry titles and 12th out of 271 Neurosciences titles in the Journal Citations Reports® published by Clarivate Analytics. The 2019 Impact Factor score for Biological Psychiatry is 12.095. http://www.sobp.org/journal
About Elsevier
Elsevier is a global information analytics business that helps scientists and clinicians to find new answers, reshape human knowledge, and tackle the most urgent human crises. For 140 years, we have partnered with the research world to curate and verify scientific knowledge. Today, we're committed to bringing that rigor to a new generation of platforms. Elsevier provides digital solutions and tools in the areas of strategic research management, R&D performance, clinical decision support, and professional education; including ScienceDirect, Scopus, SciVal, ClinicalKey and Sherpath. Elsevier publishes over 2,500 digitized journals, including The Lancet and Cell, 39,000 e-book titles and many iconic reference works, including Gray's Anatomy. Elsevier is part of RELX, a global provider of information-based analytics and decision tools for professional and business customers. http://www.elsevier.comMedia contact
Rhiannon Bugno, Editorial OfficeBiological Psychiatry
+1 254 522 9700
Biol.Psych@sobp.org
Journal
Biological Psychiatry